CMS should keep oral phosphate-lowering therapies outside the dialysis payment bundle

As a nephrologist, it is my mission to promote equal health care access and to end racial disparities in the care of patients with kidney disease.
More than 37 million Americans have chronic kidney disease, and Black people are disproportionately affected, being 4.2 times more likely to develop kidney failure compared with white people.
The General Accounting Office (GAO) recently released a report reviewing plans by CMS to include phosphate-lowering therapies (PLTs) in the End-Stage Renal Disease Prospective Payment System (PPS) by 2025. In the report, the GAO wrote the addition of PLTs “may

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart